

Endnotes

1. [Alnylam® Pharmaceuticals](#) focuses on the discovery, development, and commercialization of ribonucleic acid interference therapeutics for genetically defined diseases.

[View in Article](#)

2. Sheryl Jacobson, Mukund Lal, Dr. Jay Bhatt, Leena Gupta, Apoorva Singh, and Wendell Miranda, "[Is generative AI changing the game for medtech?](#)" *Deloitte Insights*, Oct. 15, 2024.

[View in Article](#)

3. Jim Rowan, Beena Ammanath, Costi Perricos, Brenna Sniderman, and David Jarvis, "[Deloitte's State of Generative AI in the Enterprise quarter three report](#)," Deloitte, August 2024.

[View in Article](#)

4. James Ryseff, Brandon F. De Bruhl, and Sydne J. Newberry, "[The root causes of failure for artificial intelligence projects and how they can succeed](#)," RAND, Aug. 13, 2024.

[View in Article](#)

5. Evaluate, "[Official website](#)," accessed November 2024.

[View in Article](#)

6. Alex Blair and Namrita Negi, "[More competition in oncology, state regs may impact biopharma](#)," Nov. 2, 2023; BioSpace, "[Oncology market size to exceed USD 521.60 billion by 2033 | CAGR 8.9%](#)," April 16, 2024.

[View in Article](#)

7. A growing share of FDA-approved drugs are orphan drugs. In 2023, half of all new drugs were orphan drugs; in 2013, that share was one-third. See: Food and Drug Administration (FDA), "[Novel drug approvals for 2022](#)," accessed Nov. 5, 2024; FDA, "[2022 biological license application approvals](#)," accessed Nov. 5, 2024; FDA, "[Advancing health through innovation: New drug therapy approvals 2023](#)," accessed Nov. 5, 2024; Brian Corvino, John Jaeger, Natasha Elsner, and Madhushree Wagh, "[Rethinking market access: Delivering on the promise of therapeutic innovation](#)," *Deloitte Insights*, March 9, 2022.

[View in Article](#)

8. World Health Organization, "[Obesity and overweight](#)," March 1, 2024.

[View in Article](#)

9. Jonathan Goldney and Melanie J. Davies, "[GLP1 agonists: Current and future landscape of clinical trials for patients with metabolic dysfunction](#)," *Nature Reviews Gastroenterol Hepatol* 21 (2024): pp. 664–666; Grant Playter, "[Beyond weight loss: Novo and Lilly look to expand their GLP-1 pipelines](#)," BioSpace, July 22, 2024.

[View in Article](#)

10. Megan Molteni, "[In the era of GLP-1 drugs, demand for bariatric surgery plunges](#)," STAT News, Oct. 25, 2024.

[View in Article](#)

11. Duxin Sun, Wei Gao, Hongxiang Hu, and Simon Zhou, "[Why 90% of clinical drug development fails and how to improve it?](#)" *Acta Pharmaceutica Sinica B* 12, no. 7 (2022): pp. 3049–3062.

[View in Article](#)

12. Sanofi, "[Digital "twinning": Clinical trials powered by AI](#)," May 22, 2024.

[View in Article](#)

13. Several organizations, including J&J, BMS, Roche, and Moderna, have announced pipeline reductions to strategically allocate resources to their most promising prospects. See: Ben Fidler, "[Moderna to cut costs, trim pipeline in R&D revamp](#)," Biopharma Dive, Sept. 12, 2024; Ayisha Sharma, "[Roche doubles down on high-impact projects after slashing 20% of its pipeline](#)," Endpoints News, April 24, 2024; Tristan Manalac, "[J&J scraps pipeline assets including Alzheimer's and Parkinson's candidates](#)," BioSpace, Oct. 16, 2024; Ned Pagliarulo, "[Bristol Myers to cut 6% of workforce, trim drug pipeline](#)," Biopharma Dive, April 25, 2024.

[View in Article](#)

14. May, Taylor, Gupta, and Miranda, "[Unleash AI's potential](#)."

[View in Article](#)

15. Meagan Parrish, "[Pharma's R&D gamble: Picking pipeline winners in a risky field](#)," Pharma Voice, June 7, 2024.

[View in Article](#)

16. Kevin Dunleavy, "[The top 20 pharma companies by 2023 revenue](#)," Fierce Pharma, April 15, 2024.

[View in Article](#)

17. Tyler Clifford, "[Mazor Robotics \\$1.6 billion acquisition is 'beginning to pay off,' Medtronic CEO says](#)," CNBC, Jan. 14, 2020.

[View in Article](#)

18. Aaron Savit and Ian Swan, "[FDA after Chevron](#)," Axinn, March 5, 2024; Ferdous Al-Faruque, "[Experts: Chevron deference ruling could impact recent FDA regulations](#)," Regulatory Focus, July 2, 2024.

[View in Article](#)

19. Key new developments include the new guidance on the validity of clinical studies for Joint Clinical HT Assessments; initiatives to improve cancer treatments; the regulation amending Medical Devices Regulation and the In Vitro Diagnostic Regulation regarding supply disruptions; the Corporate Sustainability Due Diligence Directive; transparency in pharmaceutical pricing; the European Artificial Intelligence Act; and the European Commission's decision on the interpretation of data concerning health. See: Hogan Lovells "[Q3/2024 Life Science Law Update – Key developments for pharma & device companies in EU](#)," Oct. 31, 2024.

[View in Article](#)

20. Emily McShane, Anaya Rehman, and Honz Slipka, "[Understanding Europe's new clinical trial regulations](#)," Certara, accessed Nov. 11, 2024; European Medical Writers Association, "[Clinical trial transparency and disclosure](#)," Medical Writing 33, no. 3 (2024).

[View in Article](#)

21. JP Morgan, "[What's behind the global supply chain crisis?](#)" May 25, 2022; Supply Chain Dive, "[Extreme weather is 2024's top supply chain risk: Everstream](#)," Jan. 11, 2024.

[View in Article](#)

22. Kelly Bilodeau, "[Behind Big Pharma's layoffs — is there an end in sight?](#)" Pharma Voice, June 10, 2024; BioSpace, "[Layoff Tracker: J&J, Merck trimming workforces in China](#)," Nov. 21, 2024.

[View in Article](#)

23. Gabrielle Masson, Darren Incorvaia, and Max Bayer "[Fierce Biotech Layoff Tracker 2024: Takeda rolls out more cuts; Sage shakes up C-suite](#)," Fierce Biotech, Oct. 21, 2024.

[View in Article](#)

24. IBM, "[What is a cyberattack?](#)" accessed Oct. 11, 2024; IBM, "[Cost of a data breach report 2024](#)," accessed Oct. 10, 2024.

[View in Article](#)

25. Deloitte, "[2023 Global future of cyber survey: Building long-term value by putting cyber at the heart of the business](#)," accessed Nov. 11, 2024.

[View in Article](#)

26. Susanna Vogel and Rebecca Pifer, "[PBMs battle bipartisan scrutiny as lawmakers eye industry reform](#)," July 24, 2024; Committee on Oversight and Accountability, "[Hearing wrap up: Oversight committee exposes how PBMs undermine patient health and increase drug costs](#)," July 23, 2024.

[View in Article](#)

27. This was later delayed by the Inflation Reduction Act until 2032.

[View in Article](#)

28. Helen R. Pfister, "[340B Roundup: Trump-era rule rescinded, motion to dismiss denied & HRSA advisory opinion withdrawn](#)," Manatt, July 7, 2021.

[View in Article](#)

29. Dylan Butts, "[Trump likely to uphold CHIPS Act despite his campaign rhetoric, policy experts say](#)," CNBC, Nov. 7, 2024.

[View in Article](#)

30. Budget reconciliation is a legislative process that can only be used to reduce the deficit generally through spending reductions or revenue increases. The process allows the Senate to bypass the filibuster for budget-focused legislation, requiring only 51 votes instead of the usual 60-vote threshold. See: Richard Kogen and David Reich, "[Introduction to budget reconciliation](#)," Center on Budget and Policy Priorities, May 6, 2022.

[View in Article](#)

31. Deloitte, "[The case for change: Preparing for the future state of CRM technology in an evolving customer engagement environment](#)," Sept. 4, 2024.

[View in Article](#)

32. Marcia Costa and Emily May, "[How consumer health companies are meeting the increased expectations of a more knowledgeable and empowered consumers](#)," Deloitte Centre for Health Solutions, Sept. 20, 2024.

[View in Article](#)

33. Ned Pagliarulo, "[Lilly launches online service for home delivery of weight loss drug](#)," Biopharma Dive, Jan. 4, 2024.

[View in Article](#)

34. Pfizer, "[Pfizer launches PfizerForAll™, a digital platform that helps simplify access to healthcare](#)," Aug. 27, 2024.

[View in Article](#)

35. Dexcom, "[Stelo by Dexcom first glucose biosensor cleared by FDA as over-the-counter](#)," March 5, 2024.

[View in Article](#)

Acknowledgments

The authors would like to express their gratitude to those who contributed to this paper.

Project team: **Natasha Elsner** and **Apoorva Singh** led data analysis and interpretation and wrote key sections of the paper. **Steve Davis** provided editorial guidance. **Wendy Gerhardt** and **Maulesh Shukla** provided overall project management support.

The authors wish to thank **Vicky Levy, Rob Jacoby, Karen Taylor, and Jay Bhatt**, who contributed significantly to the interpretation of the findings, and **Terry Koch, Sheryl Jacobson, Mathias Cousin, Gregory Reh, Shoichi Negishi, Teresa Leste, Kathy Haines, Alina Klinova, Cameron McClearn, Kenji Tomino**, and **Glenn Snyder** for their additional support.

The authors would also like to thank **Ryan DeMerlis, Maxine LeSaux, Sebastian Payne, Namrita Negi, Leah Micalizzi, Mani Keita Fakeye, Christine Chang, Kate White Walters, Jaya Nagdeo, Chase Langhorne, Diana Francis, Keith Apple, Kristopher Larsen, Lisa Illif, Roxanne Lucy, Anne Phelps, and Shahira Knight** for their subject matter expertise and review.

The authors would also like to thank **Rebecca Knutsen** for her significant contributions to the editing and structuring of the paper. Additional thanks to **Prodyut Ranjan Borah, Julie Landmesser, Debra Pielack (Asay), Christina Giambrone**, and the many others who contributed to the project.

Lastly, thank you to our interviewees for taking the time to share their invaluable perspectives with us—**Evan Lippman** (Alnylam Pharmaceuticals), **Shuhei Sekiguchi** (Johnson & Johnson), and **Akiko Amakawa** (Takeda).

Cover image by: **Sofia Sergi**; Getty Images; Adobe Stock